ScripScancell has become the second biopharma company – after BioNTech – to join a UK government program designed to accelerate research into personalized cancer vaccines. The Oxford-based firm has announc
ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b
ScripBioNTech made its name and fortune with its Pfizer-partnered COVID-19 vaccine, Comirnaty, but this year could be a turning point in its bid to diversify and become a major oncology company as well. Th
ScripThe pressure on Genmab to deliver positive results from its late-stage development programs has intensified now that the most closely watched event on the company’s 2025 calendar has arrived and the r